PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the cardiovascular safety of anticancer drug immune checkpoint inhibitors (ICIs) used in patients with malignant tumors.
UNASSIGNED: Four clinical research databases that have been completed since their establishment were searched, and the odds ratios and 95% confidence intervals of each indicator were statistically calculated.
UNASSIGNED: 62 randomized controlled trial and controlled trials were included. In single drug treatment ICIs group, the overall risk of cardio cerebral Vascular disease at all levels was higher than that in the placebo/chemotherapy group. Especially in all grades of Myocarditis and above grade 3 compared with normal controls, except for pericardial lesions, other indicators have no obvious side effects.
UNASSIGNED: Single drug use of an anti-tumor ICIs may increase cardiovascular side effects risk in cancer patients, so we need to strengthen monitoring, identification and management, and timely intervention to manage ICI induced adverse events.
UNASSIGNED: Four clinical research databases that have been completed since their establishment were searched, and the odds ratios and 95% confidence intervals of each indicator were statistically calculated.
UNASSIGNED: 62 randomized controlled trial and controlled trials were included. In single drug treatment ICIs group, the overall risk of cardio cerebral Vascular disease at all levels was higher than that in the placebo/chemotherapy group. Especially in all grades of Myocarditis and above grade 3 compared with normal controls, except for pericardial lesions, other indicators have no obvious side effects.
UNASSIGNED: Single drug use of an anti-tumor ICIs may increase cardiovascular side effects risk in cancer patients, so we need to strengthen monitoring, identification and management, and timely intervention to manage ICI induced adverse events.
摘要：
■评估用于恶性肿瘤患者的抗癌药物免疫检查点抑制剂（ICIs）的心血管安全性。
■检索了自建立以来已完成的4个临床研究数据库,并统计计算各指标的比值比和95%置信区间.
■纳入了62项随机对照试验和对照试验。在单一药物治疗ICIs组中，各级心脑血管疾病的总体风险高于安慰剂/化疗组.特别是在所有级别的心肌炎和3级以上，与正常对照组相比，除了心包病变,其他指标无明显副作用。
■单独使用抗肿瘤ICIs可能会增加癌症患者心血管副作用的风险，所以我们需要加强监测，识别和管理，并及时干预管理ICI引起的不良事件。
■检索了自建立以来已完成的4个临床研究数据库,并统计计算各指标的比值比和95%置信区间.
■纳入了62项随机对照试验和对照试验。在单一药物治疗ICIs组中，各级心脑血管疾病的总体风险高于安慰剂/化疗组.特别是在所有级别的心肌炎和3级以上，与正常对照组相比，除了心包病变,其他指标无明显副作用。
■单独使用抗肿瘤ICIs可能会增加癌症患者心血管副作用的风险，所以我们需要加强监测，识别和管理，并及时干预管理ICI引起的不良事件。
